ARTICLE | Clinical News
AAT-IV regulatory update
June 8, 2009 7:00 AM UTC
Kamada submitted a BLA to FDA for its intravenous alpha-1 antitrypsin to treat alpha-antitrypsin ( AAT) deficiency. ...
Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
Kamada submitted a BLA to FDA for its intravenous alpha-1 antitrypsin to treat alpha-antitrypsin ( AAT) deficiency. ...